RF
REGN icon

Roxbury Financial’s Regeneron Pharmaceuticals REGN Stock Holding History

Roxbury Financial’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.65K Hold
9
– – ﹤0.01% 339
2026
Q1 		$6.99K Hold
9
– – 0.01% 315
2025
Q4 		$6.98K Hold
9
– – 0.01% 311
2025
Q3 		$5.08K Hold
9
– – ﹤0.01% 314
2025
Q2 		$4.73K Buy
+9
New +$5.02K ﹤0.01% 311

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Roxbury Financial's REGN Position: Q2 2026 in Review

Roxbury Financial held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 9 shares worth $5.65K. The position accounts for ﹤0.01% of the portfolio, ranked #339.

Roxbury Financial first reported a position in REGN in Q2 2025 and has held it in 5 quarters since. The position peaked at $6.99K in Q1 2026. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Roxbury Financial held 9 shares of Regeneron Pharmaceuticals worth $5.65K as of Q2 2026.
  • Roxbury Financial left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Roxbury Financial's portfolio in Q2 2026, its #339 holding.
  • Roxbury Financial first reported a position in Regeneron Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Roxbury Financial's Regeneron Pharmaceuticals position peaked at $6.99K in Q1 2026.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Roxbury Financial's 13F filing for Q2 2026, filed 1 Jul 2026.